Cidara Therapeutics, Inc.
CDTX
Κατάταξη σε μετοχές
#3181
Cidara Therapeutics, Inc. is a biotechnology company specializing in the... Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
Τιμή μετοχής
$221.38
Τελευταίος συγχρονισμός: 2026-01-08
Κεφαλαιοποίηση
$5.61B
Αλλαγή (1 ημέρα)
0.00%
Αλλαγή (1 έτος)
118.07%
Χώρα
US
Εμπόριο Cidara Therapeutics, Inc. (CDTX)
Κατηγορία
Healthcare
EPS για Cidara Therapeutics, Inc. (CDTX)
EPS στις September 2025 TTM: $-11.78
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή της μετοχής της Cidara Therapeutics, Inc., το τρέχον EPS της εταιρείας (TTM) είναι $-11.78. Στο τέλος του 2023, η εταιρεία είχε EPS $-5.25, μείωση σε σύγκριση με το EPS του 2022 που ήταν $-9.61.
Ιστορικό EPS της Cidara Therapeutics, Inc. από 2012 έως 2026
EPS στο τέλος κάθε έτους
| Έτος | EPS | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $-11.78 | -55.96% |
| 2024 | $-26.75 | 409.52% |
| 2023 | $-5.25 | -45.37% |
| 2022 | $-9.61 | -40.68% |
| 2021 | $-16.20 | -55.04% |
| 2020 | $-36.03 | 34.54% |
| 2019 | $-26.78 | -41.30% |
| 2018 | $-45.62 | -28.37% |
| 2017 | $-63.69 | -4.21% |
| 2016 | $-66.49 | 42.19% |
| 2015 | $-46.76 | -83.88% |
| 2014 | $-290.15 | 249.41% |
| 2013 | $-83.04 | 85.77% |
| 2012 | $-44.70 | 0.00% |
EPS για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | EPS | Διαφορά EPS | Χώρα |
|---|---|---|---|
| $17.32 | -247.03% |
US
|
|
| $-7.98 | -32.26% |
US
|
|
| $-5.29 | -55.09% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -335.48% |
NL
|
